Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Epttco Ltd.
The never-ending search for cancer therapies has led researchers in recent years to consider enzyme-prodrug therapy, a way by which a safe, inactive prodrug is converted into a potent cytotoxic drug at a tumor site by delivery of an activating enzyme. Epttco Ltd. intends to join together several such research efforts.
Summarizes the technologies of several companies founded within the last year. DJ Pharma Inc., EPTTCO, GeneFormatics, Inc., InterMune Pharmaceuticals Inc., Sentillion Inc.
- Drug Delivery